Skip to main content

Tessari Eben's Form 4 filing

Kiniksa Pharmaceuticals International, plcKNSA · filed Sep 3, 2025

Accession no.
0001415889-25-023587
Filed
Sep 3, 2025
Trade date
Sep 1-3, 2025
Filing delay
2 days
Rule 10b5-1 plan
Checked

This filing lists 9 non-derivative transactions and 8 derivative transactions. Open-market sales total $535.7K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Tessari EbenCIK 0001867899Officer (CHIEF OPERATING OFFICER)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Sep 1, 2025Class A Ordinary ShareMOption exerciseAcquired+1,746–F1–41,961Direct
Sep 1, 2025Class A Ordinary ShareMOption exerciseAcquired+1,773–F1–43,734Direct
Sep 1, 2025Class A Ordinary ShareMOption exerciseAcquired+2,726–F1–46,460Direct
Sep 1, 2025Class A Ordinary ShareFTax withholdingDisposed−3,022$33.49−$101,206.7843,438Direct
Sep 2, 2025Class A Ordinary ShareMOption exerciseAcquired+1,964–F1–45,402Direct
Sep 2, 2025Class A Ordinary ShareFTax withholdingDisposed−950$34.28−$32,56644,452Direct
Sep 3, 2025Class A Ordinary ShareMOption exerciseAcquired+65$15.52+$1,008.844,517Direct
Sep 3, 2025Class A Ordinary ShareMOption exerciseAcquired+15,026$15.50+$232,90359,543Direct
Sep 3, 2025Class A Ordinary ShareSSaleDisposed−15,091$35.50F3−$535,730.544,452Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Sep 1, 2025Class A Ordinary ShareAGrant or awardAcquired+9,828$0.00$09,828Direct
Sep 1, 2025Class A Ordinary ShareAGrant or awardAcquired+39,364$0.00$039,364Direct
Sep 1, 2025Class A Ordinary ShareMOption exerciseAcquired+1,746$0.00$05,235Direct
Sep 1, 2025Class A Ordinary ShareMOption exerciseDisposed−1,773$0.00$03,545Direct
Sep 1, 2025Class A Ordinary ShareMOption exerciseDisposed−2,726$0.00$02,726Direct
Sep 2, 2025Class A Ordinary ShareMOption exerciseDisposed−1,964$0.00$00Direct
Sep 3, 2025Class A Ordinary ShareMOption exerciseDisposed−65$0.00$059,935Direct
Sep 3, 2025Class A Ordinary ShareMOption exerciseDisposed−15,026$0.00$044,974Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.

Referenced by the price of 4 transactions in Table I.

F3

This transaction was executed in multiple trades through a broker-dealer at prices ranging between $35.50 and $35.53. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)